Skip to main content
Explore URMC

menu

Breast Cancer: Exemestane With or Without Entinostat in Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Research Question:
What effects (good or bad) will the study drug entinostat have on you and your cancer when given together with standard hormonal treatment called exemestane?

Basic Study Information

Purpose:
If you choose to be in this study, you will be "randomized" into one of the study groups described below. *If you are in group A, you will take entinostat (5 mg) once per week in addition to your exemestane once per day. If your doctor decides it is best for you to change your study drug dosing during the study, you will take your doses as instructed by your doctor. *If you are in group B, you will take an inactive substance (called a “placebo”) once per week in addition to your exemestane once per day. If your doctor decides to change your study drug dosing during the study, you will take your doses as instructed by your doctor.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02115282?term=E2112&rank=1
Study Reference #: CBRS-16132

Lead Researcher (Principal Investigator)

Lead Researcher: Michelle Shayne, MD

Study Contact Information

Study Coordinator: Kate Corcoran
Phone: (585) 275-7771
Email: Kathryn_Corcoran@URMC.Rochester.edu

Additional Study Details

Return to Search